Claims for Patent: 9,446,148
✉ Email this page to a colleague
Summary for Patent: 9,446,148
Title: | Carrier-antibody compositions and methods of making and using the same |
Abstract: | Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. |
Inventor(s): | Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN) |
Assignee: | Mayo Foundation for Medical Education and Research (Rochester, MN) |
Application Number: | 14/882,327 |
Patent Claims: | 1. A lyophilized composition comprising nanoparticle complexes having an outer surface, wherein each of the nanoparticle complexes comprises: albumin; between about 100 to
about 1000 bevacizumab antibodies, each having a hydrophobic Fc portion and a VEGF-binding portion, wherein the VEGF-binding portion is arranged on the outer surface of the complex; and paclitaxel; said nanoparticle complexes being lyophilized, and
wherein upon reconstitution with an aqueous solution the VEGF-binding portions of said antibodies remain arranged on the outer surface of the complexes and remain capable of binding to VEGF in vivo and the Fc portions are associated with said albumin;
and further wherein said complexes have an average size of from about 130 nm to about 800 nm.
2. The lyophilized composition of claim 1 that is stable at about 20.degree. C. to about 25.degree. C. for at least 3 months. 3. The lyophilized composition of claim 1, wherein each of the nanoparticle complexes comprises between about 400 and about 800 antibodies. 4. The lyophilized composition of claim 3, wherein less than 0.01% of nanoparticles in the composition have a size greater than 800 nm. 5. The lyophilized composition of claim 1, wherein the average size of said complexes in the composition is from greater than 800 nm to about 3.5 .mu.m. 6. The lyophilized composition of claim 1 wherein said nanoparticles complexes have an average size of approximately 160 nm. 7. The lyophilized composition of claim 1, wherein the paclitaxel is located inside the nanoparticle complexes, arranged on the outside surface of the nanoparticle complexes, or both. 8. The composition of claim 1, wherein the albumin is human serum albumin. 9. The composition of claim 1, wherein the antibodies arrange into a substantially single layer of antibodies on all or part of the surface of the complexes. 10. The composition of claim 1, wherein the complexes have an average size of approximately 160 nm and a dissociation constant between about 1.times.10.sup.-11 M and about 1.times.10.sup.-9 M. 11. A lyophilized composition comprising nanoparticle complexes having an outer surface, wherein each of the nanoparticle complexes comprises: albumin; between about 100 to about 1000 bevacizumab antibodies, each having a hydrophobic Fc portion and a VEGF-binding portion, wherein the VEGF-binding portion is arranged on the outer surface of the complex; and paclitaxel; said nanoparticle complexes being lyophilized, and wherein upon reconstitution with an aqueous solution the VEGF-binding portions of said antibodies remain arranged on the outer surface of the complexes and remain capable of binding to VEGF in vivo and the Fc portions are associated with said albumin; and further wherein said complexes have an average size of from about 130 nm to about 800 nm; wherein the lyophilized composition does not contain a bulking agent. |
Details for Patent 9,446,148
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Grifols Therapeutics Llc | ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 | albumin (human) | For Injection | 101138 | 10/21/1942 | ⤷ Try a Trial | 2034-10-06 |
Baxalta Us Inc. | BUMINATE, FLEXBUMIN | albumin (human) | Injection | 101452 | 03/03/1954 | ⤷ Try a Trial | 2034-10-06 |
Csl Behring Ag | ALBURX | albumin (human) | Injection | 102366 | 07/23/1976 | ⤷ Try a Trial | 2034-10-06 |
Grifols Biologicals Llc | ALBUTEIN | albumin (human) | Injection | 102478 | 08/15/1978 | ⤷ Try a Trial | 2034-10-06 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.